Neximmune surges on FDA nod for HPV-related cancer therapy

Neximmune

15/07/2022 16:26

** Biotech firm Neximmune Inc's shares  NEXI.O  jump 35% to
$1.94, and set for best day on record if gains hold
    ** Co says U.S. FDA has cleared its IND application for
NEXI-003, an investigational cellular therapy being developed to
treat solid tumors in patients with relapsed or refractory human
papillomavirus (HPV)-related cancers  urn:newsml:reuters.com:*:nGNX6xkkg0
    ** NEXI adds phase 1 trial will enroll patients at multiple
clinical sites across the U.S. and will include patients that
have received at least one dose of standard therapy
    ** Co also plans an expansion phase that will enroll 24 to
36 patients overall depending on the number of dose escalations;
 all patients will be followed for at least one year
    ** NEXI's stock is third most actively traded across markets
    ** About 40.1 mln shares of the Gaithersburg, Maryland-based
company have traded, ~15,612.1% of their 30-DMA volume of
256,800 shares  
    ** As of last close, stock down 68.1% YTD

 (Johann M Cherian)
 ((yohann.mcherian@thomsonreuters.com))